Back
Equal rights in autoimmunity: is Sjögren's syndrome ever 'secondary'?
Journal article

Equal rights in autoimmunity: is Sjögren's syndrome ever 'secondary'?

  • Kollert F Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland.
  • Fisher BA Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham.
  • 2020-02-07
Published in:
  • Rheumatology (Oxford, England). - 2020
RA
SLE
Sjögren’s syndrome
anti-Ro antibodies
clinical trials
genetics
histology
salivary glands
systemic sclerosis
Arthritis, Rheumatoid
Autoimmunity
Humans
Lupus Erythematosus, Systemic
Scleroderma, Systemic
Sjogren's Syndrome
English Sjögren's syndrome (SjS) accompanied by other systemic autoimmune rheumatic connective tissue diseases has historically been termed 'secondary' in contrast to 'primary' SjS as a standalone entity. However, it is a matter of a long-standing debate whether the prefixes 'primary' and 'secondary', including a temporal component, are obsolete in the terminology of SjS. We review the history and the pathophysiological, chronological, genetic, histological and clinical data underlying the concept of 'secondary' SjS. There are important unintended consequences of the nomenclature; notably 'secondary' SjS has been much less researched and is often excluded from clinical trials. We argue for further research, a change in terminology and more stringent classification. Further we highlight possible opportunities for trials in SjS and other systemic autoimmune diseases that might contribute to an advance in care for all patients with SjS.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.rero.ch/global/documents/33482
Statistics
Document views: 27 File downloads: